Paracodine (Dihydrocodeine Tartrate)

Dihydrocodeine tartrate, the active ingredient in Paracodine, is an opioid analgesic presented as a strength/form for oral use. It is used to manage moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Paracodine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Paracodine is an opioid that acts on the central nervous system to relieve pain in several clinical contexts. - Moderate to severe acute pain: provides analgesia when non‑opioid analgesics are inadequate. - Chronic cancer‑related pain: helps control persistent pain associated with malignant disease. - Post‑operative pain: reduces pain intensity after surgical procedures.

Adverse reactions to dihydrocodeine may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness or fatigue. - Dizziness: light‑headed feeling. - Dry mouth: reduced salivation. - Itching: mild skin pruritus.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Dependence or withdrawal: signs of opioid use disorder. - Low blood pressure: hypotension causing faintness. - Hallucinations: visual or auditory disturbances. - Seizures: convulsive episodes.

When prescribing Paracodine, clinicians should consider several safety aspects. - Assess pain severity: ensure opioid therapy is appropriate for the level of pain. - Review medical history: check for respiratory disorders, liver disease, or substance‑use disorder. - Monitor for sedation: advise patients not to operate machinery while drowsy. - Avoid concurrent CNS depressants: limit use with alcohol or benzodiazepines. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Dihydrocodeine may interact with a range of medicines, requiring vigilance.

Major Interactions (Avoid): - Other opioids: combined use can cause profound respiratory depression. - Benzodiazepines: additive central nervous system depression. - MAO inhibitors: risk of severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihistamines: may increase drowsiness. - Antidepressants (SSRIs/SNRIs): potential for serotonin syndrome. - CYP3A4 inhibitors (e.g., erythromycin): may raise dihydrocodeylin levels. - Alcohol: enhances sedative effects and respiratory risk.